Oyster Point Submits Phase 2 Protocol to FDA to Test OC-01 Nasal Spray for NK
News
Oyster Point Pharma has submitted a clinical protocol to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial evaluating OC-01 (varenicline) nasal spay for the treatment ... Read more